Overweight humans are resistant to the weight-reducing effects of melanocortin4-10.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2006-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JC.2005-0906PMID 16317061
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Obesity wars: molecular progress confronts an expanding epidemic.

  2004cited by this paper
• Obesity Wars: Molecular Progress Confronts an Expanding Epidemic

  2004cited by this paper
• Is nose‐to‐brain transport of drugs in man a reality?

  2004cited by this paper
• Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10.

  2003cited by this paper
• Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene.

  2003cited by this paper
• Leptin resistance - or why leptin fails to work in obesity.

  2003cited by this paper
• Monitoring of stored and available fuel by the CNS: implications for obesity

  2003cited by this paper
• Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity.

  2002cited by this paper
• Sniffing neuropeptides: a transnasal approach to the human brain

  2002cited by this paper
• Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus

  2001cited by this paper
• Leptin resistance in obesity is characterized by decreased sensitivity to proopiomelanocortin products.

  2000cited by this paper
• Elevated plasma levels of α-melanocyte stimulating hormone (α-MSH) are correlated with insulin resistance in obese men

  2000cited by this paper
• Leptin receptor, NPY, POMC mRNA expression in the diet-induced obese mouse brain.

  2000cited by this paper
• Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity.

  2000cited by this paper
• Elevated plasma levels of alpha-melanocyte stimulating hormone (alpha-MSH) are correlated with insulin resistance in obese men.

  2000cited by this paper
• Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin

  1999cited by this paper
• Serum immunoreactive-leptin concentrations in normal-weight and obese humans.

  1996cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin 4–10 Decreases Body Fat in Humans*

  year unknowncited by this paper

• Direct transport theory: From the nose to the brain

  2021cites this paper
• Road From Nose to Brain for Treatment of Alzheimer: The Bumps and Humps.

  2020cites this paper
• Evaluation of intranasal delivery route of drug administration for brain targeting.

  2018cites this paper
• The Paradox of Ectopic Melanin Synthesis in Adipose: Potential Mechanism, Benefits and Perspectives in Abating Obesity Complications

  2017cites this paper
• Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans.

  2016cites this paper
• Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in 1 Humans 2 3

  2016cites this paper
• In Obesity, HPA Axis Activity Does Not Increase with BMI, but Declines with Aging: A Meta-Analysis of Clinical Studies

  2016cites this paper
• Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles

  2015cites this paper
• Developments and new vistas in the field of melanocortins

  2015cites this paper
• Genetic aspects of human obesity.

  2014cites this paper
• Strategies to deliver peptide drugs to the brain.

  2014cites this paper
• Principles and pitfalls in the differential diagnosis and management of childhood obesities.

  2014influential citation
• Development of a new method of intranasal injection of GALP regarding clinical application to obese people

  2013cites this paper
• Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity

  2013influential citation
• [The pharmacological treatment of obesity: past, present and future].

  2012cites this paper
• Leptin receptors.

  2012cites this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cites this paper
• Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4–10) in humans causes lipolysis in white adipose tissue

  2012cites this paper
• Design, synthesis and characterisation of gurmarin and melanocortin analogues of gurmarin

  2012cites this paper
• Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.

  2011cites this paper
• Obesidades pediátricas: de la lactancia a la adolescencia

  2011cites this paper
• [Paediatric obesities: from childhood to adolescence].

  2011cites this paper
• Present and Future: Pharmacologic Treatment of Obesity

  2011cites this paper
• Peptides and their potential role in the treatment of diabetes and obesity.

  2011cites this paper
• Pharmacological Treatment of Obesity in Children and Adolescents: Present and Future

  2010cites this paper
• Bioactive Peptides for Alleviating Illness Anorexia

  2010cites this paper
• Emerging drugs for obesity therapy.

  2009cites this paper
• Brain effects of melanocortins.

  2009cites this paper
• Early life programming of obesity and metabolic disease.

  2008cites this paper
• Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction

  2008cites this paper
• Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders.

  2008cites this paper
• The central melanocortin system and the regulation of energy balance.

  2007cites this paper
• Melanocortin receptors as targets in the treatment of obesity.

  2007cites this paper
• Melanocortin-4 receptor agonists for the treatment of obesity.

  2007cites this paper
• Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease

  2007cites this paper
• Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS

  2007cites this paper
• Drug Insight: the role of leptin in human physiology and pathophysiology—emerging clinical applications

  2006cites this paper